The same viral construct was used to produce a VPR encoding the transmembrane and extracellular domains of the Her-2 receptor, which was evaluated in a phase IB-II trial including patients with advanced Her-2 (+) breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.